Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 254 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 1015550, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 45 more
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
INS018_055, Placebo
Drug
Lead sponsor
InSilico Medicine Hong Kong Limited
Industry
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 8 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
66 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Milton, Massachusetts
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Retrospective observational study- no intervention to occur.
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
Not listed
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Iowa City, Iowa • Boston, Massachusetts • St Louis, Missouri + 3 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Belumosudil, BSC
Drug · Other
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 7 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SAR156597, Placebo (for SAR156597)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Sacramento, California • Jacksonville, Florida • Chicago, Illinois + 7 more
Conditions
Cough, Idiopathic Pulmonary Fibrosis
Interventions
Orvepitant Maleate, Placebo
Drug
Lead sponsor
Nerre Therapeutics Ltd.
Industry
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 13 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
Interventions
interferon-alpha lozenges, placebo lozenges
Drug
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lubbock, Texas
Completed Not applicable Interventional

IPF mHealth Exercise Study

NCT04838275
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
12-week mHealth home exercise prescription
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
bosentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Gefapixant
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
40 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Metformin, Matching Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Simtuzumab, Simtuzumab placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
45 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more
Conditions
Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial
Interventions
Spirometer, Oximeter, Scale, ePROs (electronic patient reported outcomes)
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Artesuante, Placebo capsules
Drug · Other
Lead sponsor
Joseph C. Wu
Other
Eligibility
40 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Combination Product
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Conditions
Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
Interventions
18F-BMS-986327
Diagnostic Test
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Healthy Participants
Interventions
BMS-986278, Sildenafil, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
35 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Conditions
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Interventions
AP01
Combination Product
Lead sponsor
Avalyn Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 23 more